Emergent BioSolutions | EBS - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Akebia Therapeutics USD 362.52M 14.04M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amarin USD 645.76M 25.01M 2026-03
ANI Pharmaceuticals USD 1.42B 18.41M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Coherus Biosciences USD 258.34M 258.18M 2025-12
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Exelixis USD 2.59B 250.83M 2026-03
Glaxosmithkline GBP 62.87B 19.47B 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Ironwood Pharmaceuticals USD 434.57M 37.66M 2026-03
Lexicon Pharmaceuticals USD 268.82M 83.83M 2026-03
Lonza CHF 18.97B 164M 2025-12
Merck USD 128.68B 8.18B 2026-03
Moderna USD 11.49B 850M 2026-03
Myriad Genetics USD 673.7M 32.9M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Pacira USD 1.21B 56.38M 2026-03
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
United Therapeutics USD 6.71B 1.17B 2026-03
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Xoma USD 263.15M 39.7M 2025-09